https://www.distributedbio.com/centivax
“However, rapidly mutating or naturally polymorphic pathogens of HIV, influenza, Chagas disease, sleeping sickness, Dengue and Zika continue to pose challenges to vaccine science. Our patented breakthrough epitope focusing technology, Centivax, focuses the immune response against conserved parts of pathogens that cannot mutate, enabling Universal Vaccine design
…
our influenza program works towards being applied to the $165M animal market and $3.2B human market, we also expand studies into other critical unmet needs, such as flaviviruses and HIV.”
EbolaInfo 